The ATTRibute-CM study’s open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with both wild-type and variant amyloid cardiomyopathy , with benefits sustained through 42 months.

The V142I variant disproportionately affects individuals of Western African ancestry, with a carrier frequency of 3-4% in the U.S. Black population. These data were presented in two moderated digital posters at the American Heart Association (AHA) Scientific Sessions 2025 and were simultaneously published in JAMA Cardiology . These results in the variant and V142I subpopulations are consistent with the statistically significant results previously presented from the ATTRibute-CM study in the wild-type population, and the ATTR-CM population overall. Acoramidis is a sel

See Full Page